HCWB, a clinical-stage biotechnology company, demonstrates strong financial metrics in debt and liquidity but faces challenges with elevated interest income ratio exceeding Shariah thresholds. Business activities in biologics R&D are permissible, with no non-compliant core operations identified. Overall, the stock is classified as non-compliant due to index exclusions, though purification can mitigate impermissible income. ESG factors align well with Islamic principles, showing low risk in governance and social responsibility. Investors should monitor future financials for potential compliance improvements.